SCHEMBL14601424

SCHEMBL14601424

Oc1ccc2nc(-c3ccsc3)n(CCc3cccs3)c2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.40
KDM4E B2RXH2 4/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
TSHR P16473 3/20 0.40
HSD17B10 Q99714 2/20 0.40
MAPT P10636 2/20 0.40
PIK3CD O00329 1/20 0.38
PIK3CA P42336 1/20 0.38
PIK3CB P42338 1/20 0.38
PIK3CG P48736 1/20 0.38
MAOB P27338 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
ALDH1A1 P00352 3/20 0.37
LMNA P02545 1/20 0.37
ESR2 Q92731 1/20 0.37
RPS6KA5 O75582 1/20 0.36
DRD2 P14416 1/20 0.36
DRD3 P35462 1/20 0.36
ESR1 P03372 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14601418 0.89 JAK2 (0.42) HPGDKDM4ESMN1; SMN2TSHRHSD17B10
SCHEMBL14601423 0.85 GRIA1 (0.45) HPGDKDM4ESMN1; SMN2TSHRHSD17B10
SCHEMBL14601427 0.85 ALDH1A1 (0.44) HPGDKDM4ESMN1; SMN2TSHRHSD17B10
SCHEMBL14601420 0.84 KDM4E (0.57) HPGDKDM4ESMN1; SMN2TSHRHSD17B10
SCHEMBL14601419 0.83 KDM4E (0.43) HPGDKDM4ESMN1; SMN2TSHRHSD17B10
SCHEMBL14601416 0.83 KDM4E (0.38) HPGDKDM4ESMN1; SMN2TSHRHSD17B10
SCHEMBL14601428 0.82 KDM4E (0.54) HPGDKDM4ESMN1; SMN2TSHRHSD17B10
SCHEMBL14601422 0.81 PTGS2 (0.43) PIK3CDPIK3CAPIK3CBPIK3CGMAOB
SCHEMBL14601421 0.80 KDM4E (0.39) HPGDKDM4ESMN1; SMN2TSHRHSD17B10
SCHEMBL14601417 0.79 KDM4E (0.38) HPGDKDM4ESMN1; SMN2TSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070004713-A1 Therapeutic benimidazole compounds ASTRAZENECA AB (SE) 2007-01-04 US disclosed
US-20070004713-A1 Therapeutic benimidazole compounds ASTRAZENECA AB (SE) 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004713-A1 Therapeutic benimidazole compounds ESR2, ESRRA, ESRRB HPGD 1692/4885KDM4E 2356/4885SMN1; SMN2 3185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.